{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T02:26:32Z","timestamp":1793499992332,"version":"4.5.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:00:00Z","timestamp":1747353600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:00:00Z","timestamp":1747353600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82170223"],"award-info":[{"award-number":["82170223"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003819","name":"Natural Science Foundation of Hubei Province","doi-asserted-by":"publisher","award":["2024AFD421"],"award-info":[{"award-number":["2024AFD421"]}],"id":[{"id":"10.13039\/501100003819","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-025-06543-x","type":"journal-article","created":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T12:55:44Z","timestamp":1747400144000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Key predictors of long-term outcomes in BCMA-targeted CAR-T therapy for relapsed\/refractory multiple myeloma"],"prefix":"10.1186","volume":"23","author":[{"given":"Ning","family":"An","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiling","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Shu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songbai","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuxia","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinran","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Mu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianlin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5134-7133","authenticated-orcid":false,"given":"Chunrui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,16]]},"reference":[{"issue":"11","key":"6543_CR1","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1080\/14712598.2019.1641196","volume":"19","author":"TAI Y T","year":"2019","unstructured":"Tai Y T, Anderson K C. B cell maturation antigen (BCMA)-based immunotherapy for multiple myeloma [J]. Expert Opin Biol Ther. 2019;19(11):1143\u201356.","journal-title":"Expert Opin Biol Ther"},{"issue":"10297","key":"6543_CR2","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","volume":"398","author":"BERDEJAJG MADDURI","year":"2021","unstructured":"Madduri Berdejajg, Usmani S Z D, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study [J]. Lancet. 2021;398(10297):314\u201324.","journal-title":"Lancet"},{"issue":"8","key":"6543_CR3","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC MUNSHI","year":"2021","unstructured":"Munshi NC, Anderson L D JR. Idecabtagene vicleucel in relapsed and refractory multiple myeloma [J]. N Engl J Med. 2021;384(8):705\u201316.","journal-title":"N Engl J Med"},{"issue":"21","key":"6543_CR4","doi-asserted-by":"publisher","first-page":"2890","DOI":"10.1182\/blood.2020008936","volume":"137","author":"D WANG","year":"2021","unstructured":"Wang D, Wang J, Hu G, et al. A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed\/refractory multiple myeloma [J]. Blood. 2021;137(21):2890\u2013901.","journal-title":"Blood"},{"issue":"Supplement 1","key":"6543_CR5","doi-asserted-by":"publisher","first-page":"4564","DOI":"10.1182\/blood-2022-168610","volume":"140","author":"W CHEN","year":"2022","unstructured":"Chen W, Fu C. Phase II study of fully human BCMA-targeting CAR-T cells (zevorcabtagene autoleucel) in patients with relapsed\/refractory multiple myeloma [J]. Blood. 2022;140(Supplement 1):4564\u20135.","journal-title":"Blood"},{"issue":"11","key":"6543_CR6","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","volume":"388","author":"S RODRIGUEZ-OTERO P, AILAWADHI","year":"2023","unstructured":"Rodriguez-Otero P, Ailawadhi S. Ide-cel or standard regimens in relapsed and refractory multiple myeloma [J]. N Engl J Med. 2023;388(11):1002\u201314.","journal-title":"N Engl J Med"},{"issue":"6","key":"6543_CR7","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1200\/JCO.22.00842","volume":"41","author":"T MARTIN","year":"2023","unstructured":"Martin T, Usmani S Z, Berdeja J G, et al. Ciltacabtagene autoleucel, an Anti-B-cell maturation antigen chimeric antigen receptor T-Cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-Year Follow-Up [J]. J Clin Oncol. 2023;41(6):1265\u201374.","journal-title":"J Clin Oncol"},{"key":"6543_CR8","doi-asserted-by":"publisher","first-page":"4854","DOI":"10.1182\/blood-2023-181394","volume":"142","author":"C LI","year":"2023","unstructured":"Li C, Wang D, Yu Q, et al. Long-Term Follow-up of fully human BCMA-Targeting CAR (CT103A) in patients with relapsed\/refractory multiple myeloma [J]. Blood. 2023;142:4854.","journal-title":"Blood"},{"issue":"10","key":"6543_CR9","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.3324\/haematol.2022.282510","volume":"108","author":"E GAGELMANN N, AYUK F A, KLYUCHNIKOV","year":"2023","unstructured":"Gagelmann N, Ayuk F A, Klyuchnikov E, et al. Impact of high-risk disease on the efficacy of chimeric antigen receptor T-cell therapy for multiple myeloma: a meta-analysis of 723 patients [J]. Haematologica. 2023;108(10):2799\u2013802.","journal-title":"Haematologica"},{"issue":"1","key":"6543_CR10","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s13045-024-01555-4","volume":"17","author":"S ZANWAR","year":"2024","unstructured":"Zanwar S, Sidana S, Shune L, et al. Impact of extramedullary multiple myeloma on outcomes with Idecabtagene vicleucel [J]. J Hematol Oncol. 2024;17(1):42.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"6543_CR11","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41408-023-00820-y","volume":"13","author":"R BANSAL","year":"2023","unstructured":"Bansal R, Baksh M. Prognostic value of early bone marrow MRD status in CAR-T therapy for myeloma [J]. Blood Cancer J. 2023;13(1):47.","journal-title":"Blood Cancer J"},{"issue":"5","key":"6543_CR12","first-page":"1514","volume":"109","author":"H HASHMI","year":"2024","unstructured":"Hashmi H, Hansen D K, Peres L C, et al. Factors associated with refractoriness or early progression after Idecabtagene vicleucel in patients with relapsed\/ refractory multiple myeloma: US myeloma immunotherapy consortium real world experience [J]. Haematologica. 2024;109(5):1514\u201324.","journal-title":"Haematologica"},{"issue":"14","key":"6543_CR13","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1200\/JCO.23.02232","volume":"42","author":"N GAGELMANN","year":"2024","unstructured":"Gagelmann N, Dima D, Merz M, et al. Development and validation of a prediction model of outcome after B-Cell maturation antigen-Directed chimeric antigen receptor T-Cell therapy in relapsed\/refractory multiple myeloma [J]. J Clin Oncol. 2024;42(14):1665\u201375.","journal-title":"J Clin Oncol"},{"issue":"22","key":"6543_CR14","doi-asserted-by":"publisher","first-page":"5428","DOI":"10.1158\/1078-0432.CCR-16-0866","volume":"22","author":"SV LANDGREN O, RAJKUMAR","year":"2016","unstructured":"Landgren O, Rajkumar SV. New developments in diagnosis, prognosis, and assessment of response in multiple myeloma [J]. Clin Cancer Res. 2016;22(22):5428\u201333.","journal-title":"Clin Cancer Res"},{"issue":"16","key":"6543_CR15","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL MAUDE","year":"2014","unstructured":"maude SL, Frey N, Shaw Pa, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia [J]. N Engl J Med. 2014;371(16):1507\u201317.","journal-title":"N Engl J Med"},{"issue":"8","key":"6543_CR16","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S KUMAR","year":"2016","unstructured":"Kumar S, Paiva B, Anderson K C, et al. International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma [J]. Lancet Oncol. 2016;17(8):e328\u201346.","journal-title":"Lancet Oncol"},{"issue":"1","key":"6543_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41375-019-0660-0","volume":"34","author":"M BHUTANI","year":"2020","unstructured":"Bhutani M, Foureau D M, Atrash S, et al. Extramedullary multiple myeloma [J]. Leukemia. 2020;34(1):1\u201320.","journal-title":"Leukemia"},{"issue":"10","key":"6543_CR18","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1373\/clinchem.2005.053272","volume":"51","author":"M MOXNESS","year":"2005","unstructured":"Moxness M, Tatarewicz S, Weeraratne D, et al. Immunogenicity testing by electrochemiluminescent detection for antibodies directed against therapeutic human monoclonal antibodies [J]. Clin Chem. 2005;51(10):1983\u20135.","journal-title":"Clin Chem"},{"issue":"4","key":"6543_CR19","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.coi.2008.06.011","volume":"20","author":"L AARDEN","year":"2008","unstructured":"Aarden L, Ruuls S R Wolbinkg. Immunogenicity of anti-tumor necrosis factor antibodies-toward improved methods of anti-antibody measurement [J]. Curr Opin Immunol. 2008;20(4):431\u20135.","journal-title":"Curr Opin Immunol"},{"issue":"5","key":"6543_CR20","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.jmoldx.2020.02.007","volume":"22","author":"Y LOU","year":"2020","unstructured":"Lou Y, Chen C, Long X, et al. Detection and quantification of chimeric antigen receptor transgene copy number by droplet digital PCR versus Real-Time PCR [J]. J Mol Diagn. 2020;22(5):699\u2013707.","journal-title":"J Mol Diagn"},{"issue":"4","key":"6543_CR21","first-page":"492","volume":"139","author":"B SAN-MIGUEL J, AVET-LOISEAU H, PAIVA","year":"2022","unstructured":"San-MigueL J, Avet-Loiseau H, Paiva B, et al. Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE [J]. Blood. J Am Soc Hematol. 2022;139(4):492\u2013501.","journal-title":"J Am Soc Hematol"},{"issue":"1","key":"6543_CR22","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1182\/hematology.2021000230","volume":"2021","author":"N YEE A J, RAJE","year":"2021","unstructured":"Yee A J, Raje N. Minimal residual disease in multiple myeloma: why, when, where [J]. Hematol Am Soc Hematol Educ Program. 2021;2021(1):37\u201345.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"7897","key":"6543_CR23","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/s41586-021-04390-6","volume":"602","author":"JJ MELENHORST","year":"2022","unstructured":"Melenhorst JJ, Chen G M, Wang M, et al. Decade-long leukaemia remissions with persistence of CD4(+) CAR T cells [J]. Nature. 2022;602(7897):503\u20139.","journal-title":"Nature"},{"issue":"1","key":"6543_CR24","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13045-024-01530-z","volume":"17","author":"J XU","year":"2024","unstructured":"Xu J, Wang B Y, Yu S H, et al. Long-term remission and survival in patients with relapsed or refractory multiple myeloma after treatment with LCAR-B38M CAR T cells: 5-year follow-up of the LEGEND-2 trial [J]. J Hematol Oncol. 2024;17(1):23.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"6543_CR25","doi-asserted-by":"publisher","first-page":"e30","DOI":"10.1016\/j.clml.2019.09.622","volume":"20","author":"H AVET-LOISEAU H, LUDWIG","year":"2020","unstructured":"Avet-Loiseau H, Ludwig H, Landgren O, et al. Minimal residual disease status as a surrogate endpoint for Progression-free survival in newly diagnosed multiple myeloma studies: A Meta-analysis [J]. Clin Lymphoma Myeloma Leuk. 2020;20(1):e30\u20137.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"6543_CR26","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1001\/jamaoncol.2016.3160","volume":"3","author":"MUNSHI N C","year":"2017","unstructured":"Munshi N C, Avet-Loiseau H, Rawstron A C, et al. Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: A Meta-analysis [J]. JAMA Oncol. 2017;3(1):28\u201335.","journal-title":"JAMA Oncol"},{"issue":"5","key":"6543_CR27","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1158\/2643-3230.BCD-23-0044","volume":"4","author":"B PAIVA","year":"2023","unstructured":"Paiva B, Manrique I. Time-Dependent prognostic value of serological and measurable residual disease assessments after Idecabtagene vicleucel [J]. Blood Cancer Discov. 2023;4(5):365\u201373.","journal-title":"Blood Cancer Discov"},{"issue":"17","key":"6543_CR28","doi-asserted-by":"publisher","first-page":"3747","DOI":"10.1158\/1078-0432.CCR-24-0414","volume":"30","author":"D CHEN","year":"2024","unstructured":"Chen D, Zhu Y, Chen Z, et al. A 5-Year Follow-up clinical study of the B-cell maturation antigen chimeric antigen receptor T-cell therapy HDS269B in patients with relapsed or refractory multiple myeloma [J]. Clin Cancer Res. 2024;30(17):3747\u201356.","journal-title":"Clin Cancer Res"},{"key":"6543_CR29","doi-asserted-by":"crossref","unstructured":"Pietrobon V, Todd L A, Goswami A et al. Improving CAR T-Cell persistence [J]. Int J Mol Sci, 2021;22(19).","DOI":"10.3390\/ijms221910828"},{"issue":"1","key":"6543_CR30","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s13045-022-01301-8","volume":"15","author":"ZHAO W H","year":"2022","unstructured":"Zhao W H, Wang B Y, Chen L J, et al. Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phase 1, single-arm, open-label, multicenter study in China (LEGEND-2) [J]. J Hematol Oncol. 2022;15(1):86.","journal-title":"J Hematol Oncol"},{"issue":"7","key":"6543_CR31","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1038\/s41591-023-02415-3","volume":"29","author":"ND ANDERSON","year":"2023","unstructured":"Anderson ND, Birch J, Accogli T, et al. Transcriptional signatures associated with persisting CD19 CAR-T cells in children with leukemia [J]. Nat Med. 2023;29(7):1700\u20139.","journal-title":"Nat Med"},{"issue":"Supplement 1","key":"6543_CR32","doi-asserted-by":"publisher","first-page":"7527","DOI":"10.1182\/blood-2022-169212","volume":"140","author":"D F\u00fcRST","year":"2022","unstructured":"F\u00fcrst D, Neuchel C. Monitoring the In-Vivo expansion and persistence of CAR-T cells as a tool to help decision making in patients with aggressive B-Cell lymphoma [J]. Blood. 2022;140(Supplement 1):7527\u20138.","journal-title":"Blood"},{"key":"6543_CR33","doi-asserted-by":"crossref","unstructured":"Xu J, Chen L-J, Yang S-S et al. Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed\/refractory multiple myeloma [J]. Proceedings of the National Academy of Sciences, 2019, 116(19): 9543-51.","DOI":"10.1073\/pnas.1819745116"},{"issue":"1","key":"6543_CR34","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s00262-021-02959-8","volume":"71","author":"G ZHAO","year":"2022","unstructured":"Zhao G, Wei R. Lenalidomide enhances the efficacy of anti-BCMA CAR-T treatment in relapsed\/refractory multiple myeloma: a case report and revies of the literature [J]. Cancer Immunol Immunother. 2022;71(1):39\u201344.","journal-title":"Cancer Immunol Immunother"},{"key":"6543_CR35","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.1182\/blood-2023-181573","volume":"142","author":"Y YAN","year":"2023","unstructured":"Yan Y, Tu Y, Wu D-P, et al. BCMA CAR-T-Cell therapy in combination with Long-Term Pomalidomide is a safe and effective treatment for relapsed\/refractory multiple myeloma [J]. Blood. 2023;142:2116.","journal-title":"Blood"},{"issue":"1","key":"6543_CR36","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1158\/1078-0432.CCR-17-0344","volume":"24","author":"X WANG","year":"2018","unstructured":"Wang X, Walter M, Urak R, et al. Lenalidomide enhances the function of CS1 chimeric antigen Receptor-Redirected T cells against multiple myeloma [J]. Clin Cancer Res. 2018;24(1):106\u201319.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"6543_CR37","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1186\/s12967-023-04655-w","volume":"21","author":"D WANG","year":"2023","unstructured":"Wang D, Fu H, Que Y, et al. A novel two-step administration of XPO-1 inhibitor May enhance the effect of anti-BCMA CAR-T in relapsed\/refractory extramedullary multiple myeloma [J]. J Translational Med. 2023;21(1):812.","journal-title":"J Translational Med"},{"issue":"1","key":"6543_CR38","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1158\/2643-3230.BCD-24-0118","volume":"6","author":"D FANDREI","year":"2025","unstructured":"Fandrei D, Seiffert S, Rade M, et al. Bispecific antibodies as bridging to BCMA CAR-T cell therapy for relapsed\/refractory multiple myeloma [J]. Blood Cancer Discov. 2025;6(1):38\u201354.","journal-title":"Blood Cancer Discov"},{"issue":"4","key":"6543_CR39","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa2303379","volume":"389","author":"J SAN-MIGUEL","year":"2023","unstructured":"San-Miguel J, Dhakal B. Cilta-cel or standard care in Lenalidomide-Refractory multiple myeloma [J]. N Engl J Med. 2023;389(4):335\u201347.","journal-title":"N Engl J Med"},{"issue":"Supplement 1","key":"6543_CR40","doi-asserted-by":"publisher","first-page":"7536","DOI":"10.1182\/blood-2022-159169","volume":"140","author":"AGHAM VAN DE DONK N W","year":"2022","unstructured":"Van De Donk N W Agham, Cohen A D, et al. Ciltacabtagene autoleucel (Cilta-cel), a BCMA-Directed CAR-T cell therapy, in patients with multiple myeloma (MM) and early relapse after initial therapy: CARTITUDE-2 cohort B 18-Month Follow-up [J]. Blood. 2022;140(Supplement 1):7536\u20137.","journal-title":"Blood"},{"issue":"9","key":"6543_CR41","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1001\/jamaoncol.2024.2172","volume":"10","author":"W QIANG","year":"2024","unstructured":"Qiang W, Lu J, Jia Y, et al. B-Cell maturation Antigen\/CD19 Dual-Targeting immunotherapy in newly diagnosed multiple myeloma [J]. JAMA Oncol. 2024;10(9):1259\u201363.","journal-title":"JAMA Oncol"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-06543-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-025-06543-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-06543-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T12:55:49Z","timestamp":1747400149000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-025-06543-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,16]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6543"],"URL":"https:\/\/doi.org\/10.1186\/s12967-025-06543-x","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,16]]},"assertion":[{"value":"6 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval for this study was obtained from Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology. Informed consent were signed by all study participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Songbai Cai is employee of Nanjing IASO Medical Technology Co., Ltd. and holds interests in the company. All other authors declared no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"552"}}